BioMérieux: group net income of E432m in 2024
(CercleFinance.com) - Consolidated sales totaled E3,980m in 2024, up 10.
3% LFL on the previous year's figure of E3,675m: teported growth was +8.3% over the year.
Recurring operating income reached E673m (16.9% of sales), including a negative currency effect of E59m. LFL, recurring contributory operating income was 20% higher than in 2023.
BioMérieux says that this is above the annual target of between +12% and +17%, and represents 18.1% of sales, up 150bp on 2023, it adds.
Gross margin for the year came to E2,215m, or 55.7% of sales, up 0.7% on 2023 at constant exchange rates and consolidation scope.
Operating income came to E589m, up 48% on the E439m recorded in 2023. Net income, group share reached E432m in 2024, up 21% on the E358m recorded in 2023.
In 2025, sales growth should be at least +7% LFL, driven by the four growth drivers of the GO28 strategic plan. Operating income before non-recurring items should increase by at least +10% LFL, management says.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
3% LFL on the previous year's figure of E3,675m: teported growth was +8.3% over the year.
Recurring operating income reached E673m (16.9% of sales), including a negative currency effect of E59m. LFL, recurring contributory operating income was 20% higher than in 2023.
BioMérieux says that this is above the annual target of between +12% and +17%, and represents 18.1% of sales, up 150bp on 2023, it adds.
Gross margin for the year came to E2,215m, or 55.7% of sales, up 0.7% on 2023 at constant exchange rates and consolidation scope.
Operating income came to E589m, up 48% on the E439m recorded in 2023. Net income, group share reached E432m in 2024, up 21% on the E358m recorded in 2023.
In 2025, sales growth should be at least +7% LFL, driven by the four growth drivers of the GO28 strategic plan. Operating income before non-recurring items should increase by at least +10% LFL, management says.
Copyright (c) 2025 CercleFinance.com. All rights reserved.